• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 3. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 4. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Professional Introduction to (1-Methyl-1H-indazol-4-YL)methanol (CAS No. 1092961-12-0)

(1-Methyl-1H-indazol-4-YL)methanol, with the chemical formula C₁₀H₁₀N₂O, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its CAS number 1092961-12-0, has garnered attention due to its versatile applications in the synthesis of bioactive molecules and its potential role in drug development. The structural motif of this molecule, featuring a methyl-substituted indazole ring linked to a hydroxymethyl group, makes it a valuable intermediate in the construction of more complex pharmacophores.

The indazole core is a well-documented scaffold in medicinal chemistry, known for its presence in numerous biologically active compounds. Its aromatic system and nitrogen-rich structure contribute to favorable interactions with biological targets, making it a preferred choice for designing molecules with therapeutic potential. The addition of a hydroxymethyl group at the 4-position of the indazole ring introduces reactivity that can be exploited in further synthetic transformations, enabling the creation of diverse derivatives.

In recent years, there has been growing interest in indazole derivatives as potential candidates for treating various diseases, including cancer, inflammation, and neurological disorders. The methoxy-substituted indazole scaffold has been explored extensively for its ability to modulate enzyme activity and receptor binding. Specifically, derivatives of this type have shown promise in inhibiting kinases and other enzymes implicated in disease pathways. The compound (1-Methyl-1H-indazol-4-YL)methanol serves as a key precursor in synthesizing such derivatives, facilitating the development of novel therapeutic agents.

One of the most compelling aspects of this compound is its role in the synthesis of small-molecule inhibitors targeting protein-protein interactions. Protein-protein interactions are critical for numerous cellular processes, and dysregulation of these interactions is often associated with disease states. By designing molecules that disrupt or modulate these interactions, researchers can develop treatments that address the underlying mechanisms of disorders. The structural features of (1-Methyl-1H-indazol-4-YL)methanol, particularly its indazole ring system and hydroxymethyl functionality, make it an ideal building block for such inhibitors.

The hydroxymethyl group provides a site for further functionalization through esterification, etherification, or oxidation reactions, allowing chemists to tailor the properties of the resulting compounds. This flexibility is crucial for optimizing drug-like characteristics such as solubility, bioavailability, and metabolic stability. Additionally, the methyl group on the indazole ring can influence electronic properties and steric interactions, further enhancing the compound's utility in medicinal chemistry.

Recent studies have highlighted the importance of indazole derivatives in oncology research. Several indazole-based compounds have entered clinical trials as potential anticancer agents, demonstrating efficacy in preclinical models. The ability to modify the indazole core to introduce different substituents has led to the discovery of molecules with improved pharmacokinetic profiles and enhanced target specificity. The compound (1-Methyl-1H-indazol-4-YL)methanol is being explored as a precursor for such next-generation anticancer drugs.

The synthesis of (1-Methyl-1H-indazol-4-YL)methanol typically involves multi-step organic transformations starting from commercially available precursors. Common synthetic routes include cyclization reactions followed by functional group modifications to introduce the desired substituents. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making this compound more accessible for research applications.

In addition to its pharmaceutical applications, this compound has shown potential in materials science and chemical biology. Its unique structural features make it suitable for use as a ligand in coordination chemistry or as a probe for studying molecular interactions. Researchers are exploring its utility in developing new catalysts or sensors based on its ability to bind metal ions and other small molecules.

The growing body of research on indazole derivatives underscores their importance as a chemical scaffold with broad therapeutic applications. As new synthetic strategies are developed and our understanding of biological targets advances, compounds like (1-Methyl-1H-indazol-4-YL)methanol will continue to play a crucial role in drug discovery and development. The versatility of this molecule makes it an indispensable tool for medicinal chemists seeking to design innovative treatments for human diseases.

In conclusion, (1-Methyl-1H-indazol-4-YL)methanol (CAS No. 1092961-12-0) is a multifaceted compound with significant potential in pharmaceutical research and industrial applications. Its unique structural features and reactivity make it a valuable intermediate for synthesizing bioactive molecules targeting various diseases. As scientific understanding progresses and new methodologies emerge, this compound will undoubtedly continue to contribute to advancements in medicinal chemistry and beyond.

• 1071433-06-1(2-methyl-2H-indazole-4-carboxylic acid)
• 1092961-08-4((1-Methyl-1H-indazol-7-YL)methanol)
• 1092961-10-8((1-Methyl-1H-indazol-6-YL)methanol)
• 1053655-56-3(1-Methyl-1H-indazole-4-carbaldehyde)
• 1159511-52-0((2-methyl-2H-indazol-5-yl)methanol)
• 1071433-05-0(1-Methyl-1H-indazole-4-carboxylic acid)
• 1092961-11-9((1-Methyl-1H-indazol-5-YL)methanol)
• 1031417-46-5(2-Methyl-2H-indazole-6-carboxylic acid)
• 1031417-77-2(1-Methyl-1H-indazole-6-carboxylic acid)
• 1176754-31-6(1-Methyl-1H-indazole-5-carboxylic acid)